After helping to power the U.S. stock market’s historic recovery from April’s tariff-induced selloff, many of the momentum ...

Jonathan Krinsky, BTIG, joins 'Closing Bell' to discuss Krinksy's thoughts on why the energy sector is poised for a breakout, ...

Jonathan Krinsky, BTIG chief market technician, joins 'Money Movers' to discuss his bullish call for this small sector to ...

Waning fears that the Trump tariff war will scuttle the U.S. economy has been helping small cap stocks of late. Jonathan Krinsky, technical guru at BTIG, notes that the iShares Russell 200 exchange ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

On June 4, analysts at BTIG reiterated a Buy rating and maintained a $210 price target on Chart Industries Inc. (NYSE:GTLS).

Nov 13 (Reuters) - U.S. brokerage firm BTIG on Monday sued rival StoneX Group Inc (SNEX.O), opens new tab in San Francisco, accusing it of stealing trade secrets and seeking at least $200 million ...

Crispr's third-quarter business update highlighted progress across the company's pipeline, including patient dosing with CTX110 and expanded Vertex programs, BTIG said in a note. "CRISPR announced ...

Detailed price information for Synchrony Financial (SYF-N) from The Globe and Mail including charting and trades.

In a recent note, BTIG acknowledged that reports the Biden administration was getting ready to propose such an action marked a “watershed moment” for the cannabis industry. However ...

BTIG sees increased stability for the medtech sector in 2024 as it moves past concerns about the impact of GLP-1 weight-loss drugs, supply chain snarls, and higher interest rates. “With GLP-1 ...

BTIG analyst Jeet Mukherjee initiated coverage of Arvinas (ARVN) with a Buy rating and $69 price target The company’s lead program, vepdegestrant, is a potent ER degrader for being developed for ...